Advocacy intelligence hub — real-time data for patient organizations
Rocket Pharmaceuticals Inc. — PHASE2
Agios Pharmaceuticals, Inc. — PHASE4
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Browse all Hemolytic anemia due to red cell pyruvate kinase deficiency news →
Petros Kountouris, PhD
Cyprus Institute of Neurology and Genetics (CING)
Béatrice Gulbis, MD
Hôpital ERASME (ERASME)
María del Mar Manú Pereira, PhD
Vall d'hebron Research Institute - Vall d'Hebron Research Institute - University Hospital Vall d'Hebrón (VHIR/HUVH)
José Luis López Lorenzo
Hospital Universitario Fundación Jiménez Díaz
Ami Shah
Stanford University
View all Hemolytic anemia due to red cell pyruvate kinase deficiency specialists →